Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece - ATLAS
Study identifier:RO-2455-401-GR
ClinicalTrials.gov identifier:NCT02187926
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Observational study for the evaluation of clinical effectiveness in routine practice of Daxas® (Roflumilast), in approximately 2700 patients with severe and very severe COPD (Chronic Obstructive Pulmonary Disease) in Greece
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
2577
Study type
Observational
Age
40 Years +
Date
Study Start Date: 01 May 2011
Primary Completion Date: 01 Dec 2013
Study Completion Date: 01 Dec 2013
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Roflumilast Roflumilast will be administered according to the prescribing information of the approved label in Greece. | - |
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
